Loading clinical trials...
Loading clinical trials...
A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Conditions
Interventions
Odronextamab
Lenalidomide
+1 more
Locations
169
United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Boca Raton Clinical Research (BRCR) Global
Plantation, Florida, United States
Indiana University and Comprehensive Cancer Center
Indianapolis, Indiana, United States
Hattiesburg Clinic
Hattiesburg, Mississippi, United States
Dartmouth Cancer Center
Lebanon, New Hampshire, United States
Stony Brook University Hospital
Stony Brook, New York, United States
Start Date
December 28, 2023
Primary Completion Date
January 23, 2029
Completion Date
January 23, 2029
Last Updated
April 13, 2026
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions